Codiak BioSciences, Inc.

CDAKDelisted May 2, 2023

Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001659352

SEC filings (opens in a new tab)

Codiak BioSciences, Inc. was delisted on May 2, 2023; its insiders filed their last Form 4 on Mar 30, 2023; 27 institutions reported holding it in 13F filings for Q1 2023, worth $1.44M in total; no superinvestor held it.

Key figures

Market cap: –; Not available
Insider buys: 0; Open market, last 90 days
Insider sells: 0; Open market, last 90 days
13F holders: 27; Q1 2023, −13 vs. previous quarter
13F value: $1.44M; Reported value at the end of Q1 2023
Superinvestors holding: 0; At the end of Q1 2023

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2021: $22.9M; +686.8% year over year
Net income, FY2021: -$37.2M; No comparable prior period
Free cash flow, FY2021: -$77.4M; No comparable prior period
Revenue, Q3 FY2022: $522.0K; −54.9% year over year

Revenue flow, FY2021

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2021: $37.2M (162.0% of revenue).

Superinvestors holding CDAK, Q1 2023

Go to the superinvestors tab

No superinvestor reported holding CDAK at the end of Q1 2023.

Latest insider trades

See all insider trades

Open-market purchases and sales by Codiak BioSciences, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Mar 30, 2023 (view filing)6:01 PM ET	Mar 30	Same day	Howze YalondaSee Remarks	SSale	−1.63K	$0.1955	−$318.27	−17.9%7.46K after
Mar 30, 2023 (view filing)5:19 PM ET	Mar 29	1 day	Sathyanarayanan SriramChief Scientific Officer	SSale	−11.8K	$0.1652	−$1.94K	−100.0%0 after
Mar 30, 2023 (view filing)5:13 PM ET	Mar 28	2 days	Konstantinov KonstantinChief Technology Officer	SSale	−9.36K	$0.2001	−$1.87K	−100.0%0 after	2 lots
Mar 30, 2023 (view filing)5:13 PM ET	Mar 28	2 days	Bain LindaChief Financial Officer	SSale	−13.4K	$0.1693	−$2.27K	−100.0%0 after
Mar 30, 2023 (view filing)5:12 PM ET	Mar 29	1 day	Barna NicoleSee Remarks	SSale	−7.30K	$0.1653	−$1.21K	−60.1%4.85K after	2 lots
Mar 30, 2023 (view filing)5:12 PM ET	Mar 28	2 days	Williams Douglas EPresident & CEO	SSale	−41.7K	$0.18	−$7.50K	−84.5%7.66K after
Feb 21, 2023 (view filing)	Aug 17, 2022-Feb 17, 2023	188 daysLate	Bain LindaChief Financial Officer	SSale	−4.93K	$1.37	−$6.74K	−26.9%13.4K after	2 lots
Feb 21, 2023 (view filing)	Aug 17, 2022-Feb 17, 2023	188 daysLate	Konstantinov KonstantinChief Technology Officer	SSale	−2.70K	$1.38	−$3.71K	−26.6%7.43K after	2 lots
Feb 21, 2023 (view filing)	Aug 17, 2022-Feb 17, 2023	188 daysLate	Williams Douglas EPresident & CEO	SSale	−14.8K	$1.37	−$20.2K	−23.1%49.3K after	2 lots
Feb 21, 2023 (view filing)	Aug 17, 2022-Feb 17, 2023	188 daysLate	Sathyanarayanan SriramChief Scientific Officer	SSale	−4.69K	$1.38	−$6.47K	−28.5%11.8K after	2 lots

Top 10 13F holders, Q1 2023

See all 27 holders

The largest institutional positions in Codiak BioSciences, Inc. at the end of Q1 2023; share changes are against Q4 2022.

Institutions holding CDAK in Q1 2023
Institution	Shares	Value	% of portfolio	Change in shares	Action
Flagship Pioneering Inc.	3,540,636	$617.8K	0.02%	00.0%	Unchanged
Laurion Capital Management LP	2,013,300	$351.3K	0.02%	00.0%	Unchanged
University of Texas/Texas Am Investment Managment Co	847,108	$148.0K	0.06%	00.0%	Unchanged
Vanguard Group Inc	580,770	$101.3K	0.00%	−242,966−29.5%	Reduced
FMR LLC	448,539	$78.3K	0.00%	−4,157,054−90.3%	Reduced
Ensign Peak Advisors, Inc	252,782	$44.1K	0.00%	00.0%	Unchanged
Millennium Management LLC	161,957	$28.0K	0.00%	−138,854−46.2%	Reduced
Forefront Analytics, LLC	110,210	$19.2K	0.01%	+10,275+10.3%	Added
Parametrica Management Ltd	65,098	$11.0K	0.02%	00.0%	Unchanged
Bank of America Corp	53,055	$9.23K	0.00%	+4,483+9.2%	Added